Shire says Daytrana action is looming

The FDA's decision to treat Shire's resubmission of Daytrana--a transdermal patch for attention deficit hyperactivity disorder for children 6 to 12--has led the company to conclude that it should get the agency's decision on the therapy early next month. The FDA had issued an approvable letter for Daytrana in December, asking for more information. If they get the FDA's approval, Shire expects to launch the treatment in the first half of this year.

- here's the AFX report